AdaptHealth Corp vs Barclays PLC — how do they compare? AdaptHealth Corp trades at $5.65 (market cap $759.10M), while Barclays PLC trades at $27.97 (market cap $94.10B). The key difference: Barclays PLC is far larger — about 124× AdaptHealth Corp's market cap, and Barclays PLC pays a 2.18% dividend while AdaptHealth Corp pays none. Which is the better fit depends on your goals.
| AHCO | BCS | |
|---|---|---|
Market Cap | $759.10M | $94.10B |
Sector | Health | Financials |
52-Week High | $13.38 | $28.56 |
52-Week Low | $5.22 | $19.36 |
Enterprise Value | $2.78B | — |
Dividend Yield | — | 2.18% |
Signals from Pluang's Aura AI — not financial advice
AdaptHealth Corp. (AHCO) trades at $5.69, down 5.87% in the last 24 hours, reflecting negative sentiment after recent earnings misses and lowered guidance. The stock shows a bearish technical signal with support near $5, while fundamentals reveal revenue of $3.24 billion in 2025 but a net loss of $70.79 million, with profitability metrics like net margin at -6.82% indicating operational challenges. Recent news highlights multiple law firm investigations into potential securities fraud following disappointing Q2 2026 results.
The outlook for AHCO is cautious due to persistent earnings underperformance and rising costs from fixed-price contracts. While analyst consensus remains bullish with a $11.00 price target, significant risks include ongoing legal scrutiny, margin pressure, and execution uncertainties. Investors should weigh the high institutional buy ratings against fundamental weaknesses and recent negative developments.
Barclays PLC (BCS) trades at $27.93, down 0.89% on the day, with a bullish technical signal from moving averages but neutral oscillators. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $0.90 exceeding the $0.89 estimate. Revenue grew to $29.14 billion in 2025, with a net income margin of 25.51%. Analyst consensus is 68% buy, though recent news highlights a securities class action investigation.
The outlook for BCS is positive given earnings momentum and a low P/E of 10.73, but risks include the legal investigation and rising costs noted in Q2 2026. Investment opportunity lies in valuation discount and dividend yield, while sentiment is mixed due to near-term headwinds.
Trailing returns across standard periods
Latest headlines on both assets
AdaptHealth provides patient-centered healthcare-at-home solutions in the U.S. It offers medical equipment and supplies for sleep therapy, respiratory health, diabetes management, and general home wellness.
Read more on AHCO →Barclays is a universal bank headquartered in the United Kingdom. It operates via two principal segments
Read more on BCS →